

## NCoA-3 (H-270): sc-13066

### BACKGROUND

Nuclear receptors for steroids, thyroid hormones and retinoic acids are ligand-dependent transcription factors that activate transcription through specific DNA binding sites in their target genes. Several related transcriptional co-activators and co-repressors have been described that work in concert with the steroid receptor family to either induce or repress transcription from hormone-responsive elements. This family includes GRIP1 (for GR interacting protein 1), also designated NCoA-2 or TIF2; SRC-1 (for steroid receptor co-activator-1), also designated NCoA-1; NCoA-3, also designated RAC-3, ACTR, AIB-1 (for amplified in breast cancer); and p/CIP (for p300/CBP/co-integrator protein), which displays elevated expression in estrogen receptor positive ovarian and breast cancers and is required for the transcriptional activation of p300/CBP-dependent transcription factors.

### CHROMOSOMAL LOCATION

Genetic locus: NCOA3 (human) mapping to 20q13.12; Ncoa3 (mouse) mapping to 2 H3.

### SOURCE

NCoA-3 (H-270) is a rabbit polyclonal antibody raised against amino acids 351-620 of NCoA-3 of human origin.

### PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Available as TransCruz reagent for Gel Supershift and ChIP applications, sc-13066 X, 200 µg/0.1 ml.

### APPLICATIONS

NCoA-3 (H-270) is recommended for detection of NCoA-3 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

NCoA-3 (H-270) is also recommended for detection of NCoA-3 in additional species, including equine, canine, bovine and porcine.

Suitable for use as control antibody for NCoA-3 siRNA (h): sc-29636, NCoA-3 siRNA (m): sc-29637, NCoA-3 shRNA Plasmid (h): sc-29636-SH, NCoA-3 shRNA Plasmid (m): sc-29637-SH, NCoA-3 shRNA (h) Lentiviral Particles: sc-29636-V and NCoA-3 shRNA (m) Lentiviral Particles: sc-29637-V.

NCoA-3 (H-270) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.

Molecular Weight of NCoA-3: 160 kDa.

Positive Controls: MIA PaCa-2 cell lysate: sc-2285, HeLa nuclear extract: sc-2120 or HeLa whole cell lysate: sc-2200.


### RESEARCH USE

For research use only, not for use in diagnostic procedures.

### STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

### DATA



NCoA-3 (H-270): sc-13066. Western blot analysis of NCoA-3 expression in MIA PaCa-2 whole cell lysate.

### SELECT PRODUCT CITATIONS

1. Kuang, S.Q., et al. 2004. AIB1/SRC-3 deficiency affects Insulin-like growth factor I signaling pathway and suppresses v-Ha-Ras-induced breast cancer initiation and progression in mice. *Cancer Res.* 64: 1875-1885.
2. Tilli, M.T., et al. 2005. Overexpression of an N-terminally truncated isoform of the nuclear receptor co-activator amplified in breast cancer 1 leads to altered proliferation of mammary epithelial cells in transgenic mice. *Mol. Endocrinol.* 19: 644-656.
3. Desai, S.J., et al. 2006. Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications. *Cancer Res.* 66: 10449-10459.
4. Mc Ilroy, M., et al. 2006. Tamoxifen-induced ER- $\alpha$ -SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence. *Endocr. Relat. Cancer* 13: 1135-1145.
5. Al-azawi, D., et al. 2008. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. *Oncogene* 27: 3021-3031.
6. Barnett, D.H., et al. 2008. Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. *Cancer Res.* 68: 3505-3515.
7. Poulard, C., et al. 2012. Activation of rapid oestrogen signalling in aggressive human breast cancers. *EMBO Mol. Med.* 4: 1200-1213.

### PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) or our catalog for detailed protocols and support products.

**MONOS**  
Satisfaction  
Guaranteed

Try **NCoA-3 (F-2): sc-5305** or **NCoA-3 (B-3): sc-515530**, our highly recommended monoclonal alternatives to NCoA-3 (H-270).